SCHEMBL5724709

SCHEMBL5724709

O=C(Nc1ccc(C2CCN2C(c2ccccc2)c2ccccc2)c(F)c1O)OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
F10 P00742 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
ELANE P08246 6/20 0.38
F2 P00734 1/20 0.38
PRSS1 P07477 1/20 0.38
HRH1 P35367 1/20 0.38
CASP3 P42574 2/20 0.37
HTT P42858 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MGLL Q99685 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
PLAU P00749 1/20 0.37
LMNA P02545 1/20 0.37
CYP3A4 P08684 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CTRC Q99895 3/20 0.37
CASP1 P29466 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5724804 0.77 PREP (0.42) NPC1RAB9AF10HRH3L3MBTL1
SCHEMBL5724950 0.76 FKBP1A (0.43) NPC1RAB9AHRH3ELANEALDH1A1
SCHEMBL7492933 0.74 TMEM97 (0.45) HRH3L3MBTL1ALDH1A1LMNA
SCHEMBL5726753 0.73 OPRM1 (0.44) ALDH1A1
SCHEMBL16609952 0.71 NPC1 (0.53) NPC1RAB9AF10CASP3HTT
SCHEMBL4669567 0.69 FKBP1A (0.50) NPC1RAB9ASMN1; SMN2
SCHEMBL12892596 0.65 RAB9A (0.57) NPC1RAB9AF10HRH3CASP3
SCHEMBL8115672 0.65 ALDH1A1 (0.63) NPC1RAB9ACASP3L3MBTL1MGLL
SCHEMBL7008912 0.64 NPC1 (0.59) NPC1RAB9ACASP3MGLLPLAU
SCHEMBL13529179 0.64 CASP3 (0.56) NPC1RAB9AF10CASP3MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1246810-B1 PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS ORTHO MCNEIL PHARM INC (US) 2006-05-17 EP disclosed
US-6518285-B2 4-oxo-5-oxazolidineylmethyl derivatives; antibacterials which are active against numerous multidrug-resistant gram positive organisms ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-02-11 US disclosed
EP-1246810-A1 PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS Ortho-McNeil Pharmaceutical, Inc. (US) 2002-10-09 EP disclosed
US-20020103377-A1 Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-08-01 US disclosed
WO-2001046164-A1 PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103377-A1 Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials OXA1L, RPS27L, RPS27 NPC1 2994/4885RAB9A 831/4885F10 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.